GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of unpopular opinion: most of what gets said here about hazard ratio is guesswork — 40 comments in the full submission. View in context.
8.2k
c/trialwatch·submitted 2 years ago by u/pancreatitis_scare

unpopular opinion: most of what gets said here about hazard ratio is guesswork

Trial Databranch of 9 comments

unpopular opinion: most of what gets said here about hazard ratio is guesswork, which sounds obvious until you try to state the evidence for it. Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking. How to read one of these papers in…

Read the full submission and all 40 comments →

This branch

9 comments, started 2 years ago
u/yusuf_ramos129 points·2 years ago

Same. A press release is a claim about a result; the publication is the result.

replysharereportpermalink
u/hazard_ratio_halMOD95 points·2 years ago

Retitled: the original quoted a diabetes endpoint as an obesity result.

replysharereportpermalink
u/cesar_ivaturi35 points·2 years ago

Agreed. Half the arguments on this site are two people quoting different trials at each other without noticing.

replysharereportpermalink
u/pancreatitis_scareOP39 points·2 years ago

Is that intention-to-treat or completers?

replysharereportpermalink
u/tb500_tangent0 points·2 years ago

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

replysharereportpermalink
u/anders_kuusela1 point·2 years ago

phase 2 finds a dose, phase 3 measures the effect

replysharereportpermalink
load more comments (3) →

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →